BioSpace News Archive

NEXGEL, Inc. (“NEXGEL” or the “Company”), a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that it has appointed Adam Drapczuk as Chief Financial Officer, effective immediately

ClearCorrect, a Straumann Group brand and a leading manufacturer of clear aligners, announced that it is accelerating its manufacturing turnaround time, standardizing the time from case approval to shipping to a lightning fast 10 days.

Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of a variety of postexposure prophylaxis and IgG products for patients, today began commercializing HyperHEP B, a new formulation of its hepatitis B immune globulin [human] for hepatitis B postexposure prophylaxis.

Eclipse, a leading aesthetic and medical manufacturer, is pleased to announce FDA clearance of their latest medical-grade microneedling device, the MicroPen EVO.

Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Everolimus Tablets (generic for Zortress®).

The Ohio State University Wexner Medical Center, one of the nation’s top-ranked academic health centers, and DispatchHealth, a leading provider of in-home medical care, have partnered to offer patients an expanded opportunity to receive convenient and safe medical care in the comfort of their own homes.

Shareholders are invited to the following scheduled Zoom meeting, per the information circular mailed to all shareholders of record.

Benzinga Cannabis Capital Conference to be held virtually on June 3-4, 2021.

Defence’s ACCUMTM platform opens a new biotherapeutic modality by ensuring effective and distinct protein (antigen) processing by specialised antigen presenting cells (dendritic cells) consequently resulting in enhanced immune responses.

Defence is developing these transformative medicines for catastrophic illnesses and is please to provide an update on its COVID-19 vaccine program with its first lead candidate AccuVAC-PT001 (study initiated in Q4 of 2020).